MAIL ONLINE: Amgen drug extends survival in some inoperable colon cancers

Press/Media: Research

Period5 Jun 2022

Media coverage


Media coverage

  • TitleAmgen drug extends survival in some inoperable colon cancers
    Media name/outletMail Online
    Media typeWeb
    Country/TerritoryUnited Kingdom
    DescriptionJune 5 (Reuters) - The following are summaries of some of the cancer research advances being presented the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

    Amgen drug extends survival for some advanced colon cancers

    Amgen Inc's drug Vectibix led to "the longest survival ever reported" in a major trial for patients with inoperable advanced cancer originating on the left side of the colon whose tumors did not have RAS gene mutations, researchers reported on Sunday at ASCO 2022

    Amgen's monoclonal antibody, known chemically as panitumumab, belongs to a class of drugs called EGFR inhibitors. The standard treatment in many countries, however, is an anti-VEGF antibody like Roche's Avastin, which means many patients with inoperable metastatic cancer may not have been getting the most effective treatment.
    PersonsMartin Mccabe

Research Beacons, Institutes and Platforms

  • Cancer


  • colon cancer